CurrentUnitedHealthcarePolicy CSO64TN.R

Intensity-Modulated Radiation Therapy

Defines medical necessity and coverage criteria for IMRT for Tennessee Medicaid and CoverKids individuals aged 19 and older (policy applies to adults; IMRT covered without further review for individuals younger than 19). Lists proven/medically necessary indications, exception criteria for other indications, and an unproven/not medically necessary statement regarding combination with proton therapy. Provides applicable CPT/HCPCS/G-code lists and clinical background/evidence summaries.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy

Policy CodePolicy CSO64TN.R

Change TypeAdditions and revisions (06/01/2025)

Effective DateJun 1, 2025

Next Review Date

Key ActionFor requests for IMRT for conditions not listed as proven, submit case-by-case exception documentation including plan comparisons or evidence of prior adjacent irradiation per policy requirements.

POLICY UPDATE CHANGES

Added 'vulvar cancer' to the list of conditions for which IMRT for Definitive Therapy is proven and medically necessary.

Replaced 'anal cancer' with 'anus/anal canal cancer' in the list of covered primary site conditions.

Updated definition of 'Definitive Therapy'.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

Archived previous policy version CSO64TN.Q.

Age <19Pediatric auto-covered without further review

1Material coverage additions (vulvar cancer)

1Terminology replacements (anal -> anus/anal canal)

IMRT+ProtonUnproven/not covered combination

RCT & cohortEvidence Basis

Coverage Summary

This policy defines medical necessity and coverage criteria for Intensity-Modulated Radiation Therapy (IMRT) for Tennessee Medicaid and CoverKids individuals aged 19 years and older; IMRT is covered without further review for individuals younger than 19 years. The policy applies to IMRT planning and delivery and references applicable CPT/HCPCS/G-codes. IMRT is described as an advanced, highly conformal external-beam modality that modulates beam intensity to better conform dose to three-dimensional tumor volumes while minimizing dose to adjacent critical normal structures; image-guided radiotherapy (IGRT) is described as an adjunctive imaging approach used at time of treatment to improve targeting accuracy (e.g., cone beam CT). The policy scope lists proven/medically necessary indications across multiple tumor sites, notes exception criteria for case-by-case coverage, and takes a mixed coverage stance reflecting both routinely covered indications and conditional uses requiring additional justification.

Thresholds and Scope

Age applicabilityPolicy applies to individuals 19 years of age and older; IMRT covered without further review for individuals younger than 19 years.

Performance statusECOG performance status of < 2 OR Karnofsky performance status (KPS) of ≥ 70

PrognosisExpected prognosis of 4 months or greater

APBI fractionationAccelerated partial breast irradiation (APBI) using IMRT allowed up to 5 fractions

HA-WBRT fractionationHA-WBRT of up to 10 fractions is covered

HA-WBRT dose-fractionation (preferred)30 Gy in 10 fractions with memantine preferred per guideline

Medical-Necessity Criteria

Medically Necessary Exceptions / Case-by-Case Consideration

IMRT may be covered for conditions not listed as proven when at least one of the following is present (evaluated case-by-case):

ANY of the following

Absence of leptomeningeal disease
Use of clinically appropriate radiation dose and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity and demonstrated on a comparison of treatment plans for the IMRT and non-IMRT technique (e.g., three-dimensional conformal treatment plan)plan-comparison required
Requires demonstration via comparison of treatment plans
The same or an immediately adjacent area has been previously irradiated and the dose distribution must be sculpted to avoid exceeding cumulative tolerance dose of nearby normal tissue

Clinical Rationale & Guideline Evidence

IMRT permits modulation of beam intensity to improve dose conformity to target volumes and reduce dose to organs at risk, which can lower acute and chronic toxicities compared with less conformal techniques; IGRT is often used in conjunction with IMRT to ensure accurate delivery and to account for anatomic and positional changes. Guidelines and trials across tumor sites support IMRT or other advanced conformal techniques to spare normal tissues while maintaining tumor coverage — examples include strong or preferred guideline recommendations for cervical and endometrial cancers to reduce GI/GU toxicity, parotid-sparing IMRT reducing xerostomia in head and neck cancers, APBI-IMRT showing low ipsilateral breast tumor recurrence with improved cosmesis in select early breast cancer, HA-WBRT (using IMRT) plus memantine preserving cognition for brain metastases, and use of IMRT/VMAT for CNS, thoracic, pelvic, mediastinal, pancreatic and prostate indications where organ sparing or dosimetric advantages are important.

Clinical/guideline-based coverage indications and comparative conclusions

Summarized conditional recommendations and evidence-based conclusions from trials and guidelines:

Preferred or recommended uses supported by guidelines

IMRT is recommended/preferred for cervical cancer in postoperative RT to decrease acute and chronic toxicity (ASTRO: strong).

Coverage Rationale — IMRT for Definitive Therapy (summary of changes)

Definitions in the policy were revised in the current version (effective 06/01/2025) per the policy history. The exact revised definition text is not included in the provided excerpt.

Coding

IMRT Planning and Delivery CPTCPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple.
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex.
77387	Guidance for localization of target volume for delivery of radiation treatment; includes intrafraction tracking; when performed.

Proton Therapy CPTCPT

77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.

Medicare G-codes for IMRT Delivery and CompensatorHCPCS

G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator; convergent beam modulated fields, per treatment session.
G6017	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment.

Provider Actions & Requirements

Prior Authorization

Case-by-case exception requests

Requests for IMRT for conditions not listed as proven will be reviewed on a case-by-case basis and must document that at least one exception criterion is met (absence of leptomeningeal disease; a plan comparison showing a non-IMRT technique would increase clinically meaningful normal tissue toxicity; or prior/adjacent irradiation requiring sculpted dose to avoid exceeding cumulative normal-tissue tolerance).

Documentation Required

Demonstrate plan comparison when claiming necessity

When asserting that a non-IMRT technique would increase clinically meaningful normal-tissue toxicity, submit a comparison of treatment plans (e.g., IMRT versus a three-dimensional conformal plan) demonstrating the dosimetric differences that support medical necessity.

Definitions

Definitions / Terminology

Definitive TherapyRadiation treatments for cancer with a curative intent (Landsteiner et al., 2023).

IMRTIntensity-modulated radiotherapy: advanced conformal technique that modulates beam intensity to spare organs at risk.

IGRTImage-guided radiotherapy: imaging at time of treatment to improve targeting accuracy (e.g., cone beam CT).

HA-WBRTHippocampal-avoidance whole-brain radiotherapy: WBRT planned to spare hippocampal neurogenic niche to reduce cognitive decline.

DO-IMRTDysphagia-optimized IMRT: IMRT planned to reduce dose to structures related to swallowing to improve post-treatment swallowing function.

3D-CRTThree-dimensional conformal radiotherapy: a less conformal radiotherapy planning/delivery technique.

Background & Evidence Summary

External-beam radiation therapy (EBRT) delivers targeted high-energy beams to destroy cancer cells while sparing normal tissues. IMRT is an advanced EBRT technique that uses computer-controlled accelerators to modulate beam intensity across small beamlets, enabling more precise three-dimensional dose conformity to tumors and reduction of dose to surrounding critical structures. IGRT employs imaging at the time of treatment delivery to maximize accuracy and is often combined with IMRT to reduce margins and improve sparing of organs at risk. Because of these capabilities, IMRT is widely used across many clinical indications — including central nervous system tumors, head and neck, breast, prostate, gastrointestinal (including esophageal, pancreatic, and anal/anus/anal canal cancers), gynecologic malignancies (cervical, endometrial, vulvar), mediastinal disease (e.g., lymphomas, thymomas), lung cancer (stage III NSCLC with chemoradiation), and for hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) to reduce cognitive decline when appropriate. The policy reflects guideline endorsements and evidence showing IMRT’s dosimetric and clinical advantages in reducing normal tissue toxicity while maintaining tumor control in many settings.

High-level Evidence Bullets

HA-WBRT RCT evidenceNRG Oncology phase III trial shows HA-WBRT + memantine preserves cognition vs WBRT + memantine (adjusted HR 0.74; p=0.02).

APBI-IMRT randomized evidenceFlorence phase III RCT: APBI-IMRT (5 fractions) yields low 10-year IBTR and better toxicity/cosmesis vs whole-breast RT.

Parotid-sparing RCT (PARSPORT)

Revision History

06/01/2025material additionLatest

Added 'vulvar cancer' to the list of conditions for which IMRT for Definitive Therapy is proven and medically necessary.

06/01/2025material revisionLatest

Replaced 'anal cancer' with 'anus/anal canal cancer' in the list of covered primary site conditions.

06/01/2025non-material revision

Policy Summary

PayerUnitedHealthcare

PolicyIntensity-Modulated Radiation Therapy

Policy CodePolicy CSO64TN.R

Change TypeAdditions and revisions (06/01/2025)

Effective DateJun 1, 2025

Next Review Date

On This Page

Unproven and Not Medically Necessary

IMRT used in conjunction with proton beam radiation therapy

Insufficient evidence of efficacy

IMRT is conditionally recommended for definitive RT with or without chemotherapy in cervical cancer to decrease acute and chronic toxicity (ASTRO: conditional).

IMRT is preferred for endometrial cancer adjuvant external beam RT to reduce acute and late toxicity (ASTRO, ACR).

IMRT is preferred/appropriate to minimize dose to bowel and other critical structures post-hysterectomy and for treating para-aortic nodes or gross regional lymph nodes (NCCN cervical/uterine guidelines).

IMRT (with IGRT) is preferred in esophageal cancer when reduction in dose to OAR (heart, lungs) is required; IMRT is standardly used preoperative, definitive and postoperative (NCCN).

IMRT is preferred for many head and neck cancer subsites to reduce long-term toxicity (xerostomia, sparing salivary glands, temporal lobes, cochlea, optic structures) (NCCN).

HA-WBRT plus memantine is effective to preserve cognitive function versus WBRT + memantine for brain metastases with no metastases near hippocampus (NCCN; randomized trials).

Dysphagia-optimized IMRT (DO-IMRT) improved patient-reported swallowing vs standard IMRT in oropharyngeal/pharyngeal cancers (phase 3 trial).

Parotid-sparing IMRT significantly reduces incidence of xerostomia vs conventional RT (randomized trials).

IMRT may reduce bowel obstruction and acute GI toxicity versus 3D-CRT/standard RT in postoperative pelvic RT for endometrial/cervical cancers (retrospective/cohort studies).

Findings of no difference or site-specific cautions

Some trials show no significant difference in overall survival or locoregional control between IMRT and 3D-CRT/CRT in certain settings (e.g., glioblastoma retrospective cohort; some head and neck RCTs for disease outcomes).
IMRT should not be used as a routine alternative to brachytherapy for central disease in intact cervix (NCCN).
Dose escalation in esophageal cancer up to 61.6 Gy did not significantly improve local control or survival versus 50.4 Gy (RCT).
IMRT can increase low-dose spread to larger volumes of normal tissue in some contexts (guideline caution regarding trade-offs; mediastinal lymphoma literature reports higher breast doses with IMRT).

High-value Evidence Summaries

HA-WBRT cognition trial (NRG CCOO1 / Brown et al.)Phase III randomized trial (n=518): HA-WBRT + memantine reduced risk of cognitive failure vs WBRT + memantine (adjusted HR 0.74; p=0.02) with no OS or intracranial PFS detriment

APBI-IMRT (Florence trial)Phase III randomized trial (Meattini et al., 2020): APBI-IMRT in 5 fractions showed low 10‑year ipsilateral breast tumor recurrence and improved toxicity/cosmesis

Parotid-sparing IMRT (PARSPORT)Randomized trial: IMRT vs conventional RT reduced grade ≥2 xerostomia at 12 and 24 months (38% vs 74% at 12 months)

Endometrial trial (NRG Oncology-RTOG 1203 / Klopp et al.)Phase III trial (278 pts): pelvic IMRT had smaller declines in EPIC bowel and urinary scores vs standard RT; fewer frequent diarrhea episodes and less antidiarrheal use

NRG/NRG Oncology analyses (RTOG 0617 secondary)Secondary analyses: IMRT associated with lower heart dose metrics and reduced grade ≥3 pneumonitis; similar OS/PFS in stage III NSCLC

Vulvar cancer retrospective seriesSingle-center retrospective series (Richman, Rishi): dose-escalated IMRT ± chemo showed high complete response rates and acceptable toxicity

Mediastinal lymphoma systematic reviewBuglione et al. (2021): IMRT improved/equivalent PTV coverage and reduced mean dose to heart/esophagus vs APPA/3D-CRT, but increased low-dose to breasts

Anal cancer trials/cohorts (RTOG 0529, Kachnic et al.)Prospective phase II and cohort analyses: DP-IMRT associated with reduced acute hematologic and GI toxicity and good control rates vs historical CRT

Documentation Required

Use of IGRT with IMRT

Document routine use of image-guided radiotherapy (orthogonal imaging or volumetric imaging such as cone beam CT) at the time of treatment delivery when delivering IMRT to ensure target coverage and OAR sparing; IGRT is recommended by NCCN/ESGO and related guidance.

Documentation Required

Avoid substituting brachytherapy with IMRT for intact cervix central disease

Do not substitute IMRT routinely for brachytherapy when treating central disease in an intact cervix; this is a guideline-based documentation and best-practice recommendation from NCCN.

Documentation Required

Hippocampal avoidance constraints and eligibility

For hippocampal-avoidance WBRT (HA-WBRT), document that there are no metastases within 5 mm of the hippocampus and that the patient’s prognosis/performance status meets guideline recommendations before offering HA-WBRT plus memantine.

Documentation Required

Consideration of technique selection

When selecting IMRT or other conformal techniques, document the specific dosimetric benefit for sparing critical OARs and note consideration of potential increased low-dose exposure to larger normal-tissue volumes (the “low-dose bath”), particularly relevant for mediastinal lymphoma and breast dose trade-offs.

Note

Check federal/state/contractual requirements

Follow federal, state, or contractual benefit plan requirements when they differ from this policy; those governing documents take precedence in the event of conflict.

Prior Authorization

Prior authorization / policy use

UnitedHealthcare Medical Policies guide interpretation of standard benefit plans; UnitedHealthcare may require prior authorization and may use third-party tools (e.g., InterQual). Providers must follow any plan-specific prior authorization procedures.

Documentation Required

Policy versioning

Reference the policy effective and revision history and archived prior versions when submitting documentation; archived version CSO64TN.Q is available.

Note on duplicate/updated Definitive TherapyPolicy notes duplicate/updated 'Definitive Therapy' entries; exact updated text not included in the excerpt.

Phase III RCT: parotid-sparing IMRT significantly reduces xerostomia at 12 and 24 months vs conventional RT.

Endometrial pelvic IMRT RCTNRG Oncology-RTOG 1203: pelvic IMRT resulted in smaller declines in EPIC bowel and urinary scores vs standard RT (phase III).

NRG / RTOG analyses (RTOG 0617)Secondary analyses: IMRT associated with lower heart doses and less severe pneumonitis; similar survival outcomes in stage III NSCLC.

Guideline endorsementsMultiple specialty guidelines (ASTRO, NCCN, ACR, ESGO) endorse IMRT or advanced techniques for specific indications (cervical, endometrial, CNS, head & neck, mediastinal lymphoma, vulvar).

Definitions section updated: definition of 'Definitive Therapy' revised.

06/01/2025non-material revisionLatest

Supporting Information updated: Description of Services, Clinical Evidence, and References sections refreshed per Policy History.

06/01/2025archivedLatest

Archived previous policy version CSO64TN.Q.